 |
|
|
| |
Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting
or Bictegravir/Emtricitabine/Tenofovir Alafenamide
|
| |
| |
CROI 2023 Feb 20-23
Darrell H. S. Tan1, Andrea Antinori2, Beng Eu3, María José Galindo Puerto4, Clifford Kinder5,
Donna Sweet6, Cornelius N. Van Dam7, Kenneth Sutton8, Denise Sutherland-Phillips8, Alessandro Berni9, Feifan Zhang10, William R. Spreen8, Harmony P. Garges8, Parul Patel8, Ronald D'Amico8
1Division of Infectious Diseases, Department of Medicine, St Michael's Hospital, Toronto, ON, Canada;
2HIV/AIDS Department, National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, Rome, Italy; 3Prahran Market Clinic, Prahran, Victoria, Australia; 4Universitat de València, Valencia, Spain; 5AIDS Healthcare Foundation–The Kinder Medical Group, Miami, FL, United States;
6University of Kansas School of Medicine-Wichita, KS, United States; 7Regional Center for Infectious Diseases, Cone Health, Greensboro, NC, United States; 8ViiV Healthcare, Durham, NC, United States; 9GSK, Brentford, United Kingdom; 10GSK, Collegeville, PA, United States
Darrell Tan, MD, PhD, reports salary support from the Canada Research Chairs Program, investigator-initiated research grants to his institution from Abbott and Gilead Sciences, Inc., and support to his institution for clinical trials sponsored by GSK
|
| |
|
|
|
|
|
